Smallpox Vaccine Trial Results Called “Encouraging”

British vaccine maker Acambis PLC yesterday announced “encouraging” results from continuing testing of its experimental smallpox vaccine, Reuters reported (see GSN, July 25, 2005).

“With these Phase 2 clinical trial results, we achieve another milestone in our program to develop MVA3000. Both the safety and immunogenicity results are in line with our expectations about MVA3000, with the results from our Phase 1 trial of the vaccine and with previous data on other MVA vaccines,” the company said in a statement.

Acambis is seeking the U.S. contract for a weaker smallpox vaccine that could be used for the elderly or patients with compromised immune systems, according to Reuters.

Bavarian Nordic of Denmark is seeking the same contract (Reuters/Boston Globe, July 31).

Back to top
About Newswire  |  Contact National Journal  |  Re-Use Guidelines © Copyright 2008 by National Journal Group, Inc. The material in this section is produced independently for NTI by National Journal Group, Inc. Any reproduction or retransmission, in whole or in part, is a violation of federal law and is strictly prohibited without the consent of the National Journal Group, Inc. All rights reserved.